NRAS and acute myeloid leukemia: KDM5A mutation was only identified in two patients with s‐AML (8.69%, 2/23), and always co‐occurred with MUC16 and TP53 mutations (100% 2/2), and co‐occurred with SRSF2 and NRAS in 50% (1/2) patients (Figure 9A).